E Bisaccia, C Berger, AS Klainer - Annals of Internal Medicine, 1990 - Am Coll Physicians Measurements and Main Results: Symptoms resolved in four patients. Lymphadenopathy disappeared
in all five. Four patients had delayed-hypersensitivity reactions to skin testing (as defined by the
Walter Reed staging classification). All showed increases in p24 and gp120 antibody ... Cited by 49 - Related articles - All 2 versions
- ►nih.gov [PDF] PW Heald, MI Perez, I Christensen, N … - The Yale Journal of …, 1989 - pubmedcentral.nih.gov Over the past two years, the photopheresis treatment program at Yale-New Haven Hospital has
treated 32 patients with cutaneous T-cell lymphoma. There were 19 erythrodermic patients who
had photopheresis as their first systemic therapy. Five of these cleared 75 percent of their ... Cited by 58 - Related articles - All 3 versions
SE Malawista, DH Trock, RL Edelson, I … - Arthritis Care & … - interscience.wiley.com In a 6-month pilot study of 7 patients with rheumatoid arthritis, we tested a treatment involving
the extracorporeal photoactivation of biologically inert methoxsalen (8-methoxypsoralen) by
ultraviolet A energy to a form that covalently cross-links lymphocyte DNA; the injured cells ... Cited by 73 - Related articles - All 3 versions
- ►nih.gov [PDF] AH Rook, B Freundlich, GT Nahass, R … - The Yale Journal of …, 1989 - pubmedcentral.nih.gov In this report, we describe the use of extracorporeal photochemotherapy in the treatment of two
patients with rapidly advancing progressive systemic sclerosis. Both patients experienced improvement
in the cutaneous as well as the systemic manifestations of their disease while undergoing ... Cited by 37 - Related articles - All 3 versions
AH Rook, BV Jegasothy, P Heald, GT … - Annals of Internal …, 1990 - Am Coll Physicians The extracorporeal exposure of pathogenic peripheral blood leukocytes to the natural compound
8-methoxypsoralen (8-MOP) and ultraviolet A radiation has provided great benefit in certain advanced
forms of cutaneous T-cell lymphoma (1). Extracorporeal photochemotherapy was given to ... Cited by 113 - Related articles - All 2 versions
PW Heald, RL Edelson - Advances in dermatology, 1988 - ncbi.nlm.nih.gov Photopheresis is a relatively safe and technically simple modality for immunomodulation. The
extracorporeal activation of a drug with UVA constitutes a novel form of drug delivery. The usefulness
of this system in erythrodermic CTCL is well established. Immunomodulating therapy can ... Cited by 34 - Related articles
JP Randazzo, FX DiSpaltro, C Cottrill, AS Klainer, … - Journal of the American …, 1994 - Elsevier Journal of the American Academy of Dermatology 908 Randazzo et at. May 1994 bility of mice
to experimental phycomycosis. J Moo Miclear leukocytes in infection by retroviruses with emphasis
crobiol 1975;8:551-64. on the human immunodeficiency virus. Viral Immunol 26. Waldorf ... Cited by 8 - Related articles - BL Direct - All 5 versions
J Gonzalez, C Berger, CM Cottrill, A Geller … - Photochemistry and …, 1996 - interscience.wiley.com Extracorporeal photochemotherapy (photopheresis), an immunomodulatory therapy that targets
circulating T helper lymphocytes, has been applied to the management of human immunodeficiency
virus (HIV) disease. Any therapy that exerts its actions on CD4 + T cells has the potential ... Cited by 8 - Related articles - BL Direct - All 4 versions
JS Wieselthier, TL Rothstein, TL Yu, T Anderson, … - Am J …, 1992 - interscience.wiley.com Because extracorporeal photopheresis has been shown to be clinically effective in Sezary
syndrome, a disease characterized by a circulating malignant clone, we initiated a pilot study
of its use in B-cell chronic lymphocytic leukemia (B-CLL) to see if it could be similarly ... Cited by 10 - Related articles - All 3 versions
